924709-31-9

Upstream product

• 2075-46-9 4-nitro-1H-pyrazole 
• 1765-93-1 4-fluoroboronic acid 
• 352-34-1 4-fluoro-1-iodobenzene 

Downstream Products

• 1613395-12-2 1-[1-(4-fluorophenyl)-5-isopropoxypyrazol-4-yl]-3-[2-methyl-4-(trifluoromethyl)imidazol-1-yl]pyrrolidin-2-one 
• 1613395-93-9 5-chloro-1-(4-fluorophenyl)-4-nitro-pyrazole 
• 1613395-95-1 C₁₂H₁₂FN₃O₃ 
• 1613395-97-3 C₁₂H₁₄FN₃O 
• 1613395-99-5 C₂₁H₂₃F₄N₅O₃ 
• 1613396-01-2 C₂₂H₂₅F₄N₅O₅S 
• 1613395-13-3 1-[1-(4-fluorophenyl)-5-dimethylaminopyrazol-4-yl]-3-[2-methyl-4-(trifluoromethyl)imidazol-1-yl]pyrrolidin-2-one 
• 1613396-03-4 C₁₁H₁₁FN₄O₂ 
• 1613396-05-6 C₁₁H₁₃FN₄ 
• 1613396-07-8 C₂₀H₂₂F₄N₆O₂ 
• 1613396-09-0 C₂₁H₂₄F₄N₆O₄S 
• 1156602-69-5 4-amino-1-(4-fluorophenyl)-1H-pyrazole 
• 1613394-89-0 1-[1-(4-fluorophenyl)pyrazol-4-yl]-3-[2-methyl-4-(trifluoromethyl)imidazol-1-yl]pyrrolidin-2-one 
• 1613395-47-3 C₁₈H₁₇F₄N₅O₂ 

Relevant academic research and scientific papers

PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR

The present invention relates to a pyrrolo(pyrazolo)pyrimidine derivative having efficacy as an LRRK2 inhibitor, a preparation method therefor, and a pharmaceutical composition for preventing or treating degenerative brain diseases, containing the same.

DIAZOLE LACTAMS

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.

DIAZOLE AMIDES

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated